Endocrine, metabolic & immune disorders drug targets · 2026
Histone Deacetylase 4: The Epigenetic Hub in Degenerative Musculoskeletal Diseases.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Junyan, Wang Zhengming, Du Guoqing, Zhang Zhaozhou, Zhang Mingcai, Feng Yuanyuan, Tan Yayi, Zhao Hong, Zhang Shanshan, Xiong Yizhe, Wang Xiang, Shen Jun, Zhan Hongsheng
Аннотация
Aging has rendered Degenerative Musculoskeletal Diseases (DMDs) an increasingly significant public health burden. Growing evidence suggests that epigenetic dysregulation plays a crucial mechanistic role in the pathogenesis of DMDs. Histone Deacetylase 4 (HDAC4), known for its regulatory roles in the nervous, cardiovascular, and cancer systems, has also emerged as a central coordinator of musculoskeletal physiology and pathology. It dynamically modulates cellular metabolism in cartilage, bone, and muscle tissues. This review aims to provide a comprehensive overview of current research on HDAC4 in the context of DMDs, highlighting its roles in chondrocyte homeostasis, synovial inflammation, osteoblast-osteoclast balance, and muscle fiber atrophy. Furthermore, we explore the therapeutic potential of targeting HDAC4 for the treatment of musculoskeletal diseases, including osteoarthritis, osteoporosis, and muscle atrophy.